Did PDUFA V Pass Too Quickly?

This article notes the swift completion of negotiations between House and Senate staff on PDUFA V (the FDA Safety & Innovation Act), and asks whether the bill could have been improved with additional time to continue the negotiations. The article quotes Catalyst’s Anne McNickle, Director of Communications and Research, on the pending Supreme Court decision on the health reform law (Affordable Care Act) and its impact on timing of user fee legislation: “If the court vacated the law and the user fee bill was still under debate, it could have allowed for some significant political tinkering with PDUFA. Essentially, the user fee bill is such a big lift on its own that Congress wanted to avoid bogging it down with possible ACA-related provisions.”Did PDUFA V Pass Too Quickly?

Recent Tweets

This is fantastic news Proteus Team! Congrats to you and TennCare. As the importance of remote monitoring is realized- especially during and immediately following this COVID pandemic, TennCare will be seen as an early adopter. This will be an important…https://lnkd.in/erD_A2G

FDA continues working around the clock to combat the #COVID19 pandemic. Here is our latest update: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-april-14-2020

In @AISHealth, Catalyst’s Jeff Myers weighs in on the #SCOTUS 8-1 ruling of #CMS owing billions to health insurers in risk corridor funding, discussing while it’s mandated by law, the risk corridor program isn’t well designed to begin with. http://catalysthcc.com/2020/05/04/health-insurers-hail-scotus-ruling-in-risk-corridors-case/

In @thehill, Catalyst’s Jeff Myers argues it’s unlikely early #COVID19 treatments will have remarkably high efficacy, but it’s still worth making and having them be available options to combat the deadly #coronavirus. https://thehill.com/policy/healthcare/494936-race-for-coronavirus-vaccine-faces-early-challenges